Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer

Current Cancer Drug Targets

Volumn 12, Issue 2, 2012, Pages 170-184

  Tan, S ^a   de Vries, E G E ^a   van der Zee, A G J ^a   de Jong, S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Cervical cancer; Death receptors; E6; E7; HR HPV; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE DEOXYNUCLEOTIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BUTYRIC ACID; CARBOPLATIN; CISPLATIN; CONATUMUMAB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GEMCITABINE; LOPINAVIR; MAPATUMUMAB; PACLITAXEL; PROTEASOME; PROTEIN E6; PROTEIN E6/E7 INHIBITOR; PROTEIN E7; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RIBOZYME; SMALL INTERFERING RNA; TIGATUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CHEMORADIOTHERAPY; GENE EXPRESSION; HUMAN; NONHUMAN; REVIEW; RNA INTERFERENCE; UTERINE CERVIX CANCER; VIRUS GENOME; WART VIRUS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DNA, VIRAL; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RADIATION, IONIZING; UTERINE CERVICAL NEOPLASMS;

EID: 84856487409     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912799095135     Document Type: Review

References (166)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. Münger, K.; Baldwin, A.; Edwards, K. M.; Hayakawa, H.; Nguyen, C. L.; Owens, M.; Grace, M.; Huh, K. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 2004, 78, 11451-11460.
3. Schiffman, M.; Castle, P. E.; Jeronimo, J.; Rodriguez, A. C.; Wacholder, S. Human papillomavirus and cervical cancer. Lancet 2007, 370, 890-907.
4. zur Hausen, H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 2000, 92, 690-698.
5. Clifford, G. M.; Smith, J. S.; Aguado, T.; Franceschi, S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 2003, 89, 101-105.
6. Koutsky, L. A.; Holmes, K. K.; Critchlow, C. W.; Stevens, C. E.; Paavonen, J.; Beckmann, A. M.; DeRouen, T. A.; Galloway, D. A.; Vernon, D.; Kiviat, N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med. 1992, 327, 1272-1278.
7. Muñoz, N.; Bosch, F. X.; de Sanjose, S.; Herrero, R.; Castellsague, X.; Shah, K. V.; Snijders, P. J.; Meijer, C. J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348, 518-527.
8. Walboomers, J. M.; Jacobs, M. V.; Manos, M. M.; Bosch, F. X.; Kummer, J. A.; Shah, K. V.; Snijders, P. J.; Peto, J.; Meijer, C. J.; Muñoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189, 12-19.
9. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J. Clin. Oncol. 2008, 26, 5802-5812.
10. Duenas-Gonzalez, A.; Zarba, J. J.; Patel, F.; Alcedo, J. C.; Beslija, S.; Casanova, L.; Pattaranutaporn, P.; Hameed, S.; Blair, J. M.; Barraclough, H.; Orlando, M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J. Clin. Oncol. 2011, 29, 1678-1685.
11. de Boer, M. A.; Jordanova, E. S.; Kenter, G. G.; Peters, A. A.; Corver, W. E.; Trimbos, J. B.; Fleuren, G. J. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin. Cancer Res. 2007, 13, 132-138.
12. Hublarova, P.; Hrstka, R.; Rotterova, P.; Rotter, L.; Coupkova, M.; Badal, V.; Nenutil, R.; Vojtesek, B. Prediction of human papillomavirus 16 e6 gene expression and cervical intraepithelial neoplasia progression by methylation status. Int. J. Gynecol. Cancer 2009, 19, 321-325.
13. Wentzensen, N.; Vinokurova, S.; Knebel Doeberitz, M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 2004, 64, 3878-3884.
14. Cheung, J. L.; Cheung, T. H.; Ng, C. W.; Yu, M. Y.; Wong, M. C.; Siu, S. S.; Yim, S. F.; Chan, P. K. Analysis of human papillomavirus type 18 load and integration status from low-grade cervical lesion to invasive cervical cancer. J. Clin. Microbiol. 2009, 47, 287-293.
15. Huang, L. W.; Chao, S. L.; Lee, B. H. Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis. J. Clin. Pathol. 2008, 61, 627-631.
16. Häfner, N.; Driesch, C.; Gajda, M.; Jansen, L.; Kirchmayr, R.; Runnebaum, I. B.; Durst, M. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008, 27, 1610-1617.
17. Kadaja, M.; Isok-Paas, H.; Laos, T.; Ustav, E.; Ustav, M. Mechanism of genomic instability in cells infected with the highrisk human papillomaviruses. PLoS Pathog. 2009, 5, e1000397-e1000412.
18. Pett, M.; Coleman, N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J. Pathol. 2007, 212, 356-367.
19. Longworth, M. S.; Wilson, R.; Laimins, L. A. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. EMBO J. 2005, 24, 1821-1830.
20. Moody, C. A.; Fradet-Turcotte, A.; Archambault, J.; Laimins, L. A. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19541-19546.
21. Fradet-Turcotte, A.; Archambault, J. Recent advances in the search for antiviral agents against human papillomaviruses. Antivir. Ther. 2007, 12, 431-451.
22. Duensing, S.; Munger, K. Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene 2002, 21, 6241-6248.
23. Komori, H.; Enomoto, M.; Nakamura, M.; Iwanaga, R.; Ohtani, K. Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. EMBO J. 2005, 24, 3724-3736.
24. Münger, K.; Basile, J. R.; Duensing, S.; Eichten, A.; Gonzalez, S. L.; Grace, M.; Zacny, V. L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20, 7888-7898.
25. Cole, S. T.; Danos, O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J. Mol. Biol. 1987, 193, 599-608.
26. Huibregtse, J. M.; Scheffner, M.; Howley, P. M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991, 10, 4129-4135.
27. Scheffner, M.; Huibregtse, J. M.; Vierstra, R. D.; Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitinprotein ligase in the ubiquitination of p53. Cell 1993, 75, 495-505.
28. Huibregtse, J. M.; Scheffner, M.; Beaudenon, S.; Howley, P. M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2563-2567.
29. Huibregtse, J. M.; Scheffner, M.; Howley, P. M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol. 1993, 13, 775-784.
30. Be, X.; Hong, Y.; Wei, J.; Androphy, E. J.; Chen, J. J.; Baleja, J. D. Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry 2001, 40, 1293-1299.
31. Chen, J. J.; Hong, Y.; Rustamzadeh, E.; Baleja, J. D.; Androphy, E. J. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J. Biol. Chem. 1998, 273, 13537-13544.
32. Hengstermann, A.; Linares, L. K.; Ciechanover, A.; Whitaker, N. J.; Scheffner, M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl. Acad. Sci. U. S A. 2001, 98, 1218-1223.
33. Beaudenon, S.; Huibregtse, J. M. HPV E6, E6AP and cervical cancer. BMC Biochem. 2008, 9(Suppl 1), S4.
34. Kao, W. H.; Beaudenon, S. L.; Talis, A. L.; Huibregtse, J. M.; Howley, P. M. Human papillomavirus type 16 E6 induces selfubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 2000, 74, 6408-6417.
35. Münger, K.; Howley, P. M. Human papillomavirus immortalization and transformation functions. Virus Res. 2002, 89, 213-228.
36. Shai, A.; Pitot, H. C.; Lambert, P. F. E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res. 2010, 70, 5064-5073.
37. Crook, T.; Wrede, D.; Tidy, J. A.; Mason, W. P.; Evans, D. J.; Vousden, K. H. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet 1992, 339, 1070-1073.
38. Denk, C.; Butz, K.; Schneider, A.; Durst, M.; Hoppe-Seyler, F. p53 mutations are rare events in recurrent cervical cancer. J. Mol. Med. 2001, 79, 283-288.
39. Ikenberg, H.; Matthay, K.; Schmitt, B.; Bauknecht, T.; Kiechle-Schwarz, M.; Goppinger, A.; Pfleiderer, A. p53 mutation and MDM2 amplification are rare even in human papillomavirusnegative cervical carcinomas. Cancer 1995, 76, 57-66.
40. Lee, J. H.; Kang, Y. S.; Koh, J. W.; Park, S. Y.; Kim, B. G.; Lee, E. D.; Lee, K. H.; Park, K. B.; Seo, Y. L. p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences. Int. J. Gynecol. Cancer 1994, 4, 371-378.
41. Thomas, M.; Pim, D.; Banks, L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999, 18, 7690-7700.
42. Tommasino, M.; Accardi, R.; Caldeira, S.; Dong, W.; Malanchi, I.; Smet, A.; Zehbe, I. The role of TP53 in Cervical carcinogenesis. Hum. Mutat. 2003, 21, 307-312.
43. Baldwin, A.; Grueneberg, D. A.; Hellner, K.; Sawyer, J.; Grace, M.; Li, W.; Harlow, E.; Munger, K. Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 12463-12468.
44. th ed.; Tannock, I., Hill, R. P., Bristow, R. G;. Harrington, L., Eds.; McGraw-Hill: New York, 2004; pp 261-280.
45. Lu, C.; El Deiry, W. S. Targeting p53 for enhanced radio-and chemo-sensitivity. Apoptosis 2009, 14, 597-606.
46. Bouvard, V.; Zaitchouk, T.; Vacher, M.; Duthu, A.; Canivet, M.; Choisy-Rossi, C.; Nieruchalski, M.; May, E. Tissue and cellspecific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 2000, 19, 649-660.
47. Burns, T. F.; Bernhard, E. J.; El Deiry, W. S. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001, 20, 4601-4612.
48. Herzog, K. H.; Chong, M. J.; Kapsetaki, M.; Morgan, J. I.; McKinnon, P. J. Requirement for Atm in ionizing radiationinduced cell death in the developing central nervous system. Science 1998, 280, 1089-1091.
49. Merritt, A. J.; Potten, C. S.; Kemp, C. J.; Hickman, J. A.; Balmain, A.; Lane, D. P.; Hall, P. A. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res. 1994, 54, 614-617.
50. Song, S.; Gulliver, G. A.; Lambert, P. F. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 2290-2295.
51. Kobayashi, J.; Iwabuchi, K.; Miyagawa, K.; Sonoda, E.; Suzuki, K.; Takata, M.; Tauchi, H. Current topics in DNA double-strand break repair. J. Radiat. Res. (Tokyo) 2008, 49, 93-103.
52. Lavin, M. F.; Kozlov, S. ATM activation and DNA damage response. Cell Cycle 2007, 6, 931-942.
53. Niibe, Y.; Nakano, T.; Ohno, T.; Tsujii, H.; Oka, K. Relationship between p21/WAF-1/CIP-1 and apoptosis in cervical cancer during radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1999, 44, 297-303.
54. Oka, K.; Suzuki, Y.; Iida, H.; Nakano, T. Radiation therapy induces the p53(+)p21(-) expression in squamous cell carcinomas of the uterine cervix. Gynecol. Oncol. 2004, 93, 340-344.
55. Mujoo, K.; Watanabe, M.; Nakamura, J.; Khokhar, A. R.; Siddik, Z. H. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. J. Cancer Res. Clin. Oncol. 2003, 129, 709-718.
56. Li, J.; Wood, W. H., III; Becker, K. G.; Weeraratna, A. T.; Morin, P. J. Gene expression response to cisplatin treatment in drugsensitive and drug-resistant ovarian cancer cells. Oncogene 2007, 26, 2860-2872.
57. Qin, L. F.; Ng, I. O. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett. 2002, 175, 27-38.
58. Rabik, C. A.; Dolan, M. E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33, 9-23.
59. Butz, K.; Geisen, C.; Ullmann, A.; Spitkovsky, D.; Hoppe-Seyler, F. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int. J. Cancer 1996, 68, 506-513.
60. Huang, H.; Huang, S. Y.; Chen, T. T.; Chen, J. C.; Chiou, C. L.; Huang, T. M. Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells. J. Cell. Biochem. 2004, 91, 756-765.
61. Koivusalo, R.; Krausz, E.; Ruotsalainen, P.; Helenius, H.; Hietanen, S. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand. Cancer Res. 2002, 62, 7364-7371.
62. Koivusalo, R.; Hietanen, S. The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status. Cancer Biol. Ther. 2004, 3, 1177-1183.
63. Wesierska-Gadek, J.; Schloffer, D.; Kotala, V.; Horky, M. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int. J. Cancer 2002, 101, 128-136.
64. Butz, K.; Shahabeddin, L.; Geisen, C.; Spitkovsky, D.; Ullmann, A.; Hoppe-Seyler, F. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 1995, 10, 927-936.
65. Wallner, K. E.; Li, G. C. Effect of cisplatin resistance on cellular radiation response. Int. J. Radiat. Oncol. Biol. Phys. 1987, 13, 587-591.
66. Ahsan, A.; Hiniker, S. M.; Davis, M. A.; Lawrence, T. S.; Nyati, M. K. Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res. 2009, 69, 5108-5114.
67. Brozovic, A.; Osmak, M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett. 2007, 251, 1-16.
68. Mandic, A.; Viktorsson, K.; Molin, M.; Akusjarvi, G.; Eguchi, H.; Hayashi, S. I.; Toi, M.; Hansson, J.; Linder, S.; Shoshan, M. C. Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner. Mol. Cell. Biol. 2001, 21, 3684-3691.
69. Bertout, J. A.; Patel, S. A.; Simon, M. C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 2008, 8, 967-975.
70. Lara, P. C.; Lloret, M.; Clavo, B.; Apolinario, R. M.; Henriquez-Hernandez, L. A.; Bordon, E.; Fontes, F.; Rey, A. Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression. Radiat. Oncol. 2009, 4, 29.
71. Rofstad, E. K.; Sundfor, K.; Lyng, H.; Trope, C. G. Hypoxiainduced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer 2000, 83, 354-359.
72. An, J.; Mo, D.; Liu, H.; Veena, M. S.; Srivatsan, E. S.; Massoumi, R.; Rettig, M. B. Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell 2008, 14, 394-407.
73. Baldwin, A. S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 2001, 107, 241-246.
74. Li, J.; Jia, H.; Xie, L.; Wang, X.; Wang, X.; He, H.; Lin, Y.; Hu, L. Association of constitutive nuclear factor-kappaB activation with aggressive aspects and poor prognosis in cervical cancer. Int. J. Gynecol. Cancer 2009, 19, 1421-1426.
75. Ashkenazi, A.; Holland, P.; Eckhardt, S. G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosisinducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 2008, 26, 3621-3630.
76. Mahalingam, D.; Szegezdi, E.; Keane, M.; de Jong, S.; Samali, A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat. Rev. 2009, 35, 280-288.
77. Adhya, A. K.; Srinivasan, R.; Patel, F. D. Radiation therapy induced changes in apoptosis and its major regulatory proteins, Bcl-2, Bcl-XL, and Bax, in locally advanced invasive squamous cell carcinoma of the cervix. Int. J. Gynecol. Pathol. 2006, 25, 281-287.
78. Iwakawa, M.; Ohno, T.; Imadome, K.; Nakawatari, M.; Ishikawa, K.; Sakai, M.; Katoh, S.; Ishikawa, H.; Tsujii, H.; Imai, T. The radiation-induced cell-death signaling pathway is activated by concurrent use of cisplatin in sequential biopsy specimens from patients with cervical cancer. Cancer Biol. Ther. 2007, 6, 905-911.
79. Liu, S. S.; Cheung, A. N.; Ngan, H. Y. Differential gene expression in cervical cancer cell lines before and after ionizing radiation. Int. J. Oncol. 2003, 22, 1091-1099.
80. Ma, B. B.; Bristow, R. G.; Kim, J.; Siu, L. L. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J. Clin. Oncol. 2003, 21, 2760-2776.
81. Wakatsuki, M.; Ohno, T.; Iwakawa, M.; Ishikawa, H.; Noda, S.; Ohta, T.; Kato, S.; Tsujii, H.; Imai, T.; Nakano, T. p73 protein expression correlates with radiation-induced apoptosis in the lack of p53 response to radiation therapy for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70, 1189-1194.
82. Yim, E. K.; Lee, K. H.; Kim, C. J.; Park, J. S. Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells. Int. J. Gynecol. Cancer 2006, 16, 690-697.
83. Hougardy, B. M.; van der Zee, A. G.; van den Heuvel, F. A.; Timmer, T.; de Vries, E. G.; de Jong, S. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid. Gynecol. Oncol. 2005, 97, 353-364.
84. Duiker, E. W.; de Vries, E. G.; Mahalingam, D.; Meersma, G. J.; Boersma-van Ek, W.; Hollema, H.; Lub-de Hooge, M. N.; van Dam, G. M.; Cool, R. H.; Quax, W. J.; Samali, A.; van der Zee, A. G.; de Jong, S. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin. Cancer Res. 2009, 15, 2048-2057.
85. Bernard, H. U. Established and potential strategies against papillomavirus infections. J. Antimicrob. Chemother. 2004, 53, 137-139.
86. Alvarez-Salas, L. M.; DiPaolo, J. A. Molecular approaches to cervical cancer therapy. Curr. Drug Discov. Technol. 2007, 4, 208-219.
87. Gu, W.; Putral, L. N.; Irving, A.; McMillan, N. A. The development and future of oligonucleotide-based therapies for cervical cancer. Curr. Opin. Mol. Ther. 2007, 9, 126-131.
88. Fujii, T.; Saito, M.; Iwasaki, E.; Ochiya, T.; Takei, Y.; Hayashi, S.; Ono, A.; Hirao, N.; Nakamura, M.; Kubushiro, K.; Tsukazaki, K.; Aoki, D. Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int. J. Oncol. 2006, 29, 541-548.
89. Jonson, A. L.; Rogers, L. M.; Ramakrishnan, S.; Downs, L. S., Jr. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol. Oncol. 2008, 111, 356-364.
90. Niu, X. Y.; Peng, Z. L.; Duan, W. Q.; Wang, H.; Wang, P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int. J. Gynecol. Cancer 2006, 16, 743-751.
91. Yamato, K.; Yamada, T.; Kizaki, M.; Ui-Tei, K.; Natori, Y.; Fujino, M.; Nishihara, T.; Ikeda, Y.; Nasu, Y.; Saigo, K.; Yoshinouchi, M. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther. 2008, 15, 140-153.
92. Putral, L. N.; Bywater, M. J.; Gu, W.; Saunders, N. A.; Gabrielli, B. G.; Leggatt, G. R.; McMillan, N. A. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol. Pharmacol. 2005, 68, 1311-1319.
93. Koivusalo, R.; Krausz, E.; Helenius, H.; Hietanen, S. Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol. Pharmacol. 2005, 68, 372-382.
94. Liu, W. L.; Green, N.; Seymour, L. W.; Stevenson, M. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. Cancer Gene Ther. 2009, 16, 764-775.
95. Zheng, Y.; Zhang, J.; Rao, Z. Ribozyme targeting HPV16 E6E7 transcripts in cervical cancer cells suppresses cell growth and sensitizes cells to chemotherapy and radiotherapy. Cancer Biol. Ther. 2004, 3, 1129-1134.
96. Yamayoshi, A.; Kato, K.; Suga, S.; Ichinoe, A.; Arima, T.; Matsuda, T.; Kato, H.; Murakami, A.; Wake, N. Specific apoptosis induction in human papillomavirus-positive cervical carcinoma cells by photodynamic antisense regulation. Oligonucleotides 2007, 17, 66-79.
97. D'Abramo, C. M.; Archambault, J. Small molecule inhibitors of human papillomavirus protein-protein interactions. Open Virol. J. 2011, 5, 80-95.
98. Sterlinko Grm, H.; Weber, M.; Elston, R.; McIntosh, P.; Griffin, H.; Banks, L.; Doorbar, J. Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. J. Mol. Biol. 2004, 335, 971-985.
99. Dymalla, S.; Scheffner, M.; Weber, E.; Sehr, P.; Lohrey, C.; Hoppe-Seyler, F.; Hoppe-Seyler, K. A novel peptide motif binding to and blocking the intracellular activity of the human papillomavirus E6 oncoprotein. J. Mol. Med. (Berl) 2009, 87, 321-331.
100. Baleja, J. D.; Cherry, J. J.; Liu, Z.; Gao, H.; Nicklaus, M. C.; Voigt, J. H.; Chen, J. J.; Androphy, E. J. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res. 2006, 72, 49-59.
101. Issaeva, N.; Bozko, P.; Enge, M.; Protopopova, M.; Verhoef, L. G.; Masucci, M.; Pramanik, A.; Selivanova, G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10, 1321-1328.
102. Zhao, C. Y.; Szekely, L.; Bao, W.; Selivanova, G. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res. 2010, 70, 3372-3381.
103. Guo, C. P.; Liu, K. W.; Luo, H. B.; Chen, H. B.; Zheng, Y.; Sun, S. N.; Zhang, Q.; Huang, L. Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway. PLoS One 2011, 6, e17734.
104. Kim, M. K.; Min, J.; Choi, B. Y.; Lim, H.; Cho, Y. H.; Lee, C. H. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening. J. Microbiol. Biotechnol. 2007, 17, 1712-1716.
105. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 2009, 9, 153-166.
106. Hougardy, B. M.; Maduro, J. H.; van der Zee, A. G.; de Groot, D. J.; van den Heuvel, F. A.; de Vries, E. G.; de Jong, S. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int. J. Cancer 2006, 118, 1892-1900.
107. Pajonk, F.; Grumann, T.; McBride, W. H. The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation. Neoplasia 2006, 8, 1037-1041.
108. Yang, Y.; Kitagaki, J.; Wang, H.; Hou, D. X.; Perantoni, A. O. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 2009, 100, 24-28.
109. Kamer, S.; Ren, Q.; Dicker, A. P. Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). Arch. Gynecol. Obstet. 2009, 279, 41-46.
110. Birle, D. C.; Hedley, D. W. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res. 2007, 67, 1735-1743.
111. Pugh, T. J.; Chen, C.; Rabinovitch, R.; Eckhardt, S. G.; Rusthoven, K. E.; Swing, R.; Raben, D. Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients with Advanced Solid Malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78, 521-526.
112. A Phase I Open-labeled, Dose-escalation, Safety Study of the Combination of Velcade and Chemoradiation for the Treatment of Cancer Patients. http://www.clinicaltrials.gov/ct2/show/NCT00329589 (Accessed February 20, 2011).
113. Batman, G.; Oliver, A. W.; Zehbe, I.; Richard, C.; Hampson, L.; Hampson, I. N. Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. Antivir. Ther. 2011, 16, 515-525.
114. Hampson, L.; Kitchener, H. C.; Hampson, I. N. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir. Ther. 2006, 11, 813-825.
115. Duncan, K. J.; Eckert, K. A.; Clawson, G. A. Mechanisms of growth inhibition in human papillomavirus positive and negative cervical cancer cells by the chloromethyl ketone protease inhibitor, succinyl-alanine-alanine-proline-phenylalanine chloromethyl ketone. J. Pharmacol. Exp. Ther. 2009, 330, 359-366.
116. Drubin, D. A.; McLaughlin-Drubin, M. E.; Clawson, G. A.; Meyers, C. A protease inhibitor specifically inhibits growth of HPV-infected keratinocytes. Mol. Ther. 2006, 13, 1142-1148.
117. Batty, N.; Malouf, G. G.; Issa, J. P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009, 280, 192-200.
118. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27, 5459-5468.
119. Selvi, R. B.; Kundu, T. K. Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics. Biotechnol. J. 2009, 4, 375-390.
120. Brehm, A.; Nielsen, S. J.; Miska, E. A.; McCance, D. J.; Reid, J. L.; Bannister, A. J.; Kouzarides, T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999, 18, 2449-2458.
121. de la Cruz-Hernandez, E.; Perez-Cardenas, E.; Contreras-Paredes, A.; Cantu, D.; Mohar, A.; Lizano, M.; Duenas-Gonzalez, A. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol. J. 2007, 4, 18-28.
122. Finzer, P.; Krueger, A.; Stohr, M.; Brenner, D.; Soto, U.; Kuntzen, C.; Krammer, P. H.; Rosl, F. HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway. Oncogene 2004, 23, 4807-4817.
123. Luo, J.; Su, F.; Chen, D.; Shiloh, A.; Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408, 377-381.
124. Luczak, M. W.; Jagodzinski, P. P. Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells. Cancer Lett. 2008, 272, 53-60.
125. Lin, Z.; Bazzaro, M.; Wang, M. C.; Chan, K. C.; Peng, S.; Roden, R. B. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin. Cancer Res. 2009, 15, 570-577.
126. Spierings, D. C.; de Vries, E. G.; Vellenga, E.; van den Heuvel, F. A.; Koornstra, J. J.; Wesseling, J.; Hollema, H.; de Jong, S. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem. 2004, 52, 821-831.
127. Lee, M. W.; Park, S. C.; Kim, J. H.; Kim, I. K.; Han, K. S.; Kim, K. Y.; Lee, W. B.; Jung, Y. K.; Kim, S. S. The involvement of oxidative stress in tumor necrosis factor (TNF)-related apoptosisinducing ligand (TRAIL)-induced apoptosis in HeLa cells. Cancer Lett. 2002, 182, 75-82.
128. Straughn, J. M., Jr.; Oliver, P. G.; Zhou, T.; Wang, W.; Alvarez, R. D.; Grizzle, W. E.; Buchsbaum, D. J. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol. Oncol. 2006, 101, 46-54.
129. Ryu, H. S.; Chang, K. H.; Chang, S. J.; Kim, M. S.; Joo, H. J.; Oh, K. S. Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. Int. J. Gynecol. Cancer 2000, 10, 417-424.
130. Reesink-Peters, N.; Hougardy, B. M.; van den Heuvel, F. A.; ten Hoor, K. A.; Hollema, H.; Boezen, H. M.; de Vries, E. G.; de Jong, S.; van der Zee, A. G. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol. Oncol. 2005, 96, 705-713.
131. Shivapurkar, N.; Toyooka, S.; Toyooka, K. O.; Reddy, J.; Miyajima, K.; Suzuki, M.; Shigematsu, H.; Takahashi, T.; Parikh, G.; Pass, H. I.; Chaudhary, P. M.; Gazdar, A. F. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int. J. Cancer 2004, 109, 786-792.
132. Herbeuval, J. P.; Nilsson, J.; Boasso, A.; Hardy, A. W.; Kruhlak, M. J.; Anderson, S. A.; Dolan, M. J.; Dy, M.; Andersson, J.; Shearer, G. M. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 7000-7005.
133. Lum, J. J.; Pilon, A. A.; Sanchez-Dardon, J.; Phenix, B. N.; Kim, J. E.; Mihowich, J.; Jamison, K.; Hawley-Foss, N.; Lynch, D. H.; Badley, A. D. Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J. Virol. 2001, 75, 11128-11136.
134. Clarke, P.; Tyler, K. L. Reovirus-induced apoptosis: A minireview. Apoptosis 2003, 8, 141-150.
135. Eaton, S.; Wiktor, P.; Thirstrup, D.; Lake, D.; Nagaraj, V. J. Efficacy of TRAIL treatment against HPV16 infected cervical cancer cells undergoing senescence following siRNA knockdown of E6/E7 genes. Biochem. Biophys. Res. Commun. 2011, 405, 1-6.
136. Filippova, M.; Parkhurst, L.; Duerksen-Hughes, P. J. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 2004, 279, 25729-25744.
137. Garnett, T. O.; Filippova, M.; Duerksen-Hughes, P. J. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ. 2006, 13, 1915-1926.
138. Lagunas-Martínez, A.; Madrid-Marina, V.; Gariglio, P. Modulation of apoptosis by early human papillomavirus proteins in cervical cancer. Biochim. Biophys. Acta 2010, 1805, 6-16.
139. Sadarangani, A.; Kato, S.; Espinoza, N.; Lange, S.; Llados, C.; Espinosa, M.; Villalon, M.; Lipkowitz, S.; Cuello, M.; Owen, G. I. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 2007, 12, 73-85.
140. Maduro, J. H.; de Vries, E. G.; Meersma, G. J.; Hougardy, B. M.; van der Zee, A. G.; de Jong, S. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiationinduced apoptosis. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 543-552.
141. Darvas, K.; Rosenberger, S.; Brenner, D.; Fritsch, C.; Gmelin, N.; Krammer, P. H.; Rosl, F. Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int. J. Cancer 2010, 127, 1384-1392.
142. Hougardy, B. M.; Reesink-Peters, N.; van den Heuvel, F. A.; ten Hoor, K. A.; Hollema, H.; de Vries, E. G.; de Jong, S.; van der Zee, A. G. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int. J. Cancer 2008, 123, 1457-1465.
143. Herbst, R. S.; Eckhardt, S. G.; Kurzrock, R.; Ebbinghaus, S.; O'Dwyer, P. J.; Gordon, M. S.; Novotny, W.; Goldwasser, M. A.; Tohnya, T. M.; Lum, B. L.; Ashkenazi, A.; Jubb, A. M.; Mendelson, D. S. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 2010, 28, 2839-2846.
144. Soria, J. C.; Smit, E.; Khayat, D.; Besse, B.; Yang, X.; Hsu, C. P.; Reese, D.; Wiezorek, J.; Blackhall, F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 1527-1533.
145. Reis, C. R.; van der Sloot, A. M.; Szegezdi, E.; Natoni, A.; Tur, V.; Cool, R. H.; Samali, A.; Serrano, L.; Quax, W. J. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry 2009, 48, 2180-2191.
146. van der Sloot, A. M.; Tur, V.; Szegezdi, E.; Mullally, M. M.; Cool, R. H.; Samali, A.; Serrano, L.; Quax, W. J. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 8634-8639.
147. Gasparian, M. E.; Chernyak, B. V.; Dolgikh, D. A.; Yagolovich, A. V.; Popova, E. N.; Sycheva, A. M.; Moshkovskii, S. A.; Kirpichnikov, M. P. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis 2009, 14, 778-787.
148. Oldenhuis, C. N.; Stegehuis, J. H.; Walenkamp, A. M.; de Jong, S.; de Vries, E. G. Targeting TRAIL death receptors. Curr. Opin. Pharmacol. 2008, 8, 433-439.
149. Wu, X. X.; Kakehi, Y. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspasedependent manner. Clin. Cancer Res. 2009, 15, 2039-2047.
150. Kendrick, J. E.; Straughn, J. M., Jr.; Oliver, P. G.; Wang, W.; Nan, L.; Grizzle, W. E.; Stockard, C. R.; Alvarez, R. D.; Buchsbaum, D. J. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol. Oncol. 2008, 108, 591-597.
151. Tolcher, A. W.; Mita, M.; Meropol, N. J.; von Mehren, M.; Patnaik, A.; Padavic, K.; Hill, M.; Mays, T.; McCoy, T.; Fox, N. L.; Halpern, W.; Corey, A.; Cohen, R. B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factorrelated apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 2007, 25, 1390-1395.
152. Greco, F. A.; Bonomi, P.; Crawford, J.; Kelly, K.; Oh, Y.; Halpern, W.; Lo, L.; Gallant, G.; Klein, J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced nonsmall cell lung cancer. Lung Cancer 2008, 61, 82-90.
153. Hotte, S. J.; Hirte, H. W.; Chen, E. X.; Siu, L. L.; Le, L. H.; Corey, A.; Iacobucci, A.; MacLean, M.; Lo, L.; Fox, N. L.; Oza, A. M. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 2008, 14, 3450-3455.
154. Trarbach, T.; Moehler, M.; Heinemann, V.; Kohne, C. H.; Przyborek, M.; Schulz, C.; Sneller, V.; Gallant, G.; Kanzler, S. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer 2010, 102, 506-512.
155. Leong, S.; Cohen, R. B.; Gustafson, D. L.; Langer, C. J.; Camidge, D. R.; Padavic, K.; Gore, L.; Smith, M.; Chow, L. Q.; von Mehren, M.; O'Bryant, C.; Hariharan, S.; Diab, S.; Fox, N. L.; Miceli, R.; Eckhardt, S. G. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J. Clin. Oncol. 2009, 27, 4413-4421.
156. Mom, C. H.; Verweij, J.; Oldenhuis, C. N.; Gietema, J. A.; Fox, N. L.; Miceli, R.; Eskens, F. A.; Loos, W. J.; de Vries, E. G.; Sleijfer, S. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin. Cancer Res. 2009, 15, 5584-5590.
157. Camidge, D. R.; Herbst, R. S.; Gordon, M. S.; Eckhardt, S. G.; Kurzrock, R.; Durbin, B.; Ing, J.; Tohnya, T. M.; Sager, J.; Ashkenazi, A.; Bray, G.; Mendelson, D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin. Cancer Res. 2010, 16, 1256-1263.
158. Forero-Torres, A.; Shah, J.; Wood, T.; Posey, J.; Carlisle, R.; Copigneaux, C.; Luo, F. R.; Wojtowicz-Praga, S.; Percent, I.; Saleh, M. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother. Radiopharm. 2010, 25, 13-19.
159. Doi, T.; Murakami, H.; Ohtsu, A.; Fuse, N.; Yoshino, T.; Yamamoto, N.; Boku, N.; Onozawa, Y.; Hsu, C. P.; Gorski, K. S.; Friberg, G.; Kawaguchi, T.; Sasaki, T. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2011, 68, 733-741.
160. Herbst, R. S.; Kurzrock, R.; Hong, D. S.; Valdivieso, M.; Hsu, C. P.; Goyal, L.; Juan, G.; Hwang, Y. C.; Wong, S.; Hill, J. S.; Friberg, G.; LoRusso, P. M. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin. Cancer Res. 2010, 16, 5883-5891.
161. A Phase 1b/2 Study With the Agonistic TRAIL-R1 Antibody, Mapatumumab, in Combination With Cisplatin and Radiotherapy as a First Line Therapy in Patients With Advanced Cervical Cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01088347 [Accessed February 20, 2011].
162. Scheffner, M.; Munger, K.; Byrne, J. C.; Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 5523-5527.
163. Tsunokawa, Y.; Takebe, N.; Nozawa, S.; Kasamatsu, T.; Gissmann, L.; zur Hausen, H.; Terada, M.; Sugimura, T. Presence of human papillomavirus type-16 and type-18 DNA sequences and their expression in cervical cancers and cell lines from Japanese patients. Int. J. Cancer 1986, 37, 499-503.
164. Takebe, N.; Tsunokawa, Y.; Nozawa, S.; Terada, M.; Sugimura, T. Conservation of E6 and E7 regions of human papillomavirus types 16 and 18 present in cervical cancers. Biochem. Biophys. Res. Commun. 1987, 143, 837-844.
165. Caceres-Cortes, J. R.; Alvarado-Moreno, J. A.; Waga, K.; Rangel-Corona, R.; Monroy-Garcia, A.; Rocha-Zavaleta, L.; Urdiales-Ramos, J.; Weiss-Steider, B.; Haman, A.; Hugo, P.; Brousseau, R.; Hoang, T. Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Res. 2001, 61, 6281-6289.
166. ATCC-LGC Standards. Available from: http://www.lgcstandardsatcc.org/ [Accessed July 19, 2011].